🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#HeadNeckCancer and its treatment can have a lasting impact on #MentalHealth and #Wellness. This is summarized in this infographic from the #AHNS. Patients should be referred to a mental health professional when appropriate!

This is a BIG deal. The first mobile screening unit in the state of Florida. Lung screening numbers across the state have been historically low. This is a huge step in changing that!

It’s official! Moffitt’s mobile lung screening unit is ready to hit the road. Our goal is to increase screening rates and save more lives.

Progress is well underway at Moffitt's newest location in Ruskin, Florida! Moffitt at SouthShore will offer a wide range of services to patients, including cancer screenings, diagnostic imaging, blood draw and clinical labs, medical oncology clinics, radiation therapy and

☀️ 🚨 Coming soon! 🚨 ☀️ See you in Boca Raton 🏝️ #FCOM2024 #thyroidnodules #thyroidcancerawareness Moffitt Cancer Center #MedTwitter #FSOHNSF

The best thyroid cancer team there is! American Thyroid Association #thyroidcancer #MedTwitter Moffitt Cancer Center

While at #SITC24 I had the pleasure of speaking with Christine Chung, MD (Christine Chung), chair of the Department of Head and Neck-Endocrine Oncology Moffitt Cancer Center, about the latest happening in the field. Check out our chat below! 👇

Thank you FCOMnow for having me!! As always, a great meeting ☀️

Floridian Head & Neck Surgeons were shining bright ☀️ at the annual FCOMnow meeting this weekend! 🌴 Moffitt Cancer Center FCOMnow #MedTwitter #thyroidcancer #skincancer #immunotherapy

Thanks for the shout out Dr. Patrick Hwu Moffitt Cancer Center !!

Protocol Activation! NRG-HN014 "Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma” is open to patient entry. conta.cc/4ftFlhD Neil D. Gross, MD, FACS

Time to get to work y’all!

Top Moffitt Research Stories of 2024 | Moffitt moffitt.org/endeavor/archi…

The NRG-HN014 patient study webpage and the patient study brochure are now live! You can access both items here: nrgoncology.org/HN014 - Check out this study of adding immunotherapy before surgery for advanced #skincancer. Neil D. Gross, MD, FACS

As emerging data on benefits of GLP-1 agonist continues to favor its utilization in select cases, a common question from patients is the safety in terms of #ThyroidCancer risks. Very relevant article to help individualize balancing the #data on risks vs benefits.

The NRG-HN014 study is testing if the + cemiplimab before response-adapted oncologic surgery & if indicated, adjuvant RT can improve survival outcomes when compared to std of care surgery & adjuvant RT for pts w/ resectable stage III/IV CSCC. ow.ly/Rs5050UGfS7 Neil D. Gross, MD, FACS

Happening now at #ASCO25: Caitlin McMullen, MD (Dr. Caitlin McMullen) joins the case-based panel on multidisciplinary treatment of anaplastic thyroid cancer. She brings the surgeon’s perspective to managing one of the most aggressive thyroid malignancies. #MoffittASCO25 ASCO

During #ASCO25, Caitlin McMullen, MD (Dr. Caitlin McMullen) and Guilherme Rabinowits, MD joined us to discuss the emerging head and neck cancer research being presented at ASCO. #MoffittASCO25

From #ASCO25, Kedar Kirtane, MD (Kedar Kirtane, MD) shares early-phase data from DENALI-1, a study of A2B395—a logic-gated, allogeneic CAR T targeting EGFR in solid tumors with HLA LOH. This novel off-the-shelf approach aims to expand CAR T therapy safely into solid tumors.

Wrapping up another amazing World Congress on Thyroid Cancer in Boston. Great lectures, caught up with old friends, and presented our research. Proud to be part of the leadership team of this organization!!! ✈️🏆👩‍🏫 #thyroidcancer #WCTC2025 Sarimar Agosto MD Moffitt Cancer Center